News

TURANDOT Revisits Bevacizumab Partners in Metastatic Breast Cancer

Publish date: October 17, 2012

 

AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS

Roche sponsored the TURANDOT trial. Dr. Zielinski disclosed receiving honoraria from the company. Dr. Javier Cortes has received honoraria from Roche.

Pages

Recommended Reading

FDA Approves Ultrasound Screening of Dense Breasts
Breast Cancer ICYMI
Everolimus Reduces Breast Cancer Treatment Effects in Bone
Breast Cancer ICYMI
California Enacts Breast Density Notification Law
Breast Cancer ICYMI
The Cure Is Here, Once Again: Walking the Tightrope Between Hype and Hope
Breast Cancer ICYMI
One Year of Trastuzumab Remains the Standard in Early Breast Cancer
Breast Cancer ICYMI
EMILIA Confirms T-DM1 Overall Survival Advantage
Breast Cancer ICYMI
Another Study Finds No Glargine, Breast Cancer Link
Breast Cancer ICYMI
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Breast Cancer ICYMI
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3)
Breast Cancer ICYMI
Baseline Factors Trump Response to Therapy in Mastectomy Decisions
Breast Cancer ICYMI